15beta-(3-propanamido)-substituted estra-1,3,5(10)-trien-17-oximes for use in inhibition of 17beta-hydroxysteroid dehydrogenases

15beta-(3-propanamido)-substituted estra-1,3,5(10)-trien-17-oximes for use in inhibition of 17beta-hydroxysteroid dehydrogenases

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereofwherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LINNANEN Tero, KOSKIMIES Pasi, STJERNSCHANTZ Camilla, HIRVELA Leena, HAKOLA Marjo
Format: Patent
Sprache:eng ; heb
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
STEROIDS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator LINNANEN Tero
KOSKIMIES Pasi
STJERNSCHANTZ Camilla
HIRVELA Leena
HAKOLA Marjo
description The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereofwherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_IL294140B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IL294140B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_IL294140B13</originalsourceid><addsrcrecordid>eNqFjLEKwkAQBdNYiPoNXhnBBc9Egq2iKFjay8Xb6ILeHrcbMJ2frgR74cHAMLxh9rarGtVBXkBMHF1wT_I8A2lrUdJW0RsUTQ7svJivcruYgSbCALYCftETxTScTCtoKHx3p5qUOBhujK3673vnE786UUxM3njsxQ2DE5RxNmjcQ3Dy4yib7nfn7QEw8gUluisG1MvxtFyXtlxsbPG_-ABVS0YX</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>15beta-(3-propanamido)-substituted estra-1,3,5(10)-trien-17-oximes for use in inhibition of 17beta-hydroxysteroid dehydrogenases</title><source>esp@cenet</source><creator>LINNANEN Tero ; KOSKIMIES Pasi ; STJERNSCHANTZ Camilla ; HIRVELA Leena ; HAKOLA Marjo</creator><creatorcontrib>LINNANEN Tero ; KOSKIMIES Pasi ; STJERNSCHANTZ Camilla ; HIRVELA Leena ; HAKOLA Marjo</creatorcontrib><description>The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereofwherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.</description><language>eng ; heb</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; STEROIDS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240501&amp;DB=EPODOC&amp;CC=IL&amp;NR=294140B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240501&amp;DB=EPODOC&amp;CC=IL&amp;NR=294140B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LINNANEN Tero</creatorcontrib><creatorcontrib>KOSKIMIES Pasi</creatorcontrib><creatorcontrib>STJERNSCHANTZ Camilla</creatorcontrib><creatorcontrib>HIRVELA Leena</creatorcontrib><creatorcontrib>HAKOLA Marjo</creatorcontrib><title>15beta-(3-propanamido)-substituted estra-1,3,5(10)-trien-17-oximes for use in inhibition of 17beta-hydroxysteroid dehydrogenases</title><description>The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereofwherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>STEROIDS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFjLEKwkAQBdNYiPoNXhnBBc9Egq2iKFjay8Xb6ILeHrcbMJ2frgR74cHAMLxh9rarGtVBXkBMHF1wT_I8A2lrUdJW0RsUTQ7svJivcruYgSbCALYCftETxTScTCtoKHx3p5qUOBhujK3673vnE786UUxM3njsxQ2DE5RxNmjcQ3Dy4yib7nfn7QEw8gUluisG1MvxtFyXtlxsbPG_-ABVS0YX</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>LINNANEN Tero</creator><creator>KOSKIMIES Pasi</creator><creator>STJERNSCHANTZ Camilla</creator><creator>HIRVELA Leena</creator><creator>HAKOLA Marjo</creator><scope>EVB</scope></search><sort><creationdate>20240501</creationdate><title>15beta-(3-propanamido)-substituted estra-1,3,5(10)-trien-17-oximes for use in inhibition of 17beta-hydroxysteroid dehydrogenases</title><author>LINNANEN Tero ; KOSKIMIES Pasi ; STJERNSCHANTZ Camilla ; HIRVELA Leena ; HAKOLA Marjo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_IL294140B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; heb</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>STEROIDS</topic><toplevel>online_resources</toplevel><creatorcontrib>LINNANEN Tero</creatorcontrib><creatorcontrib>KOSKIMIES Pasi</creatorcontrib><creatorcontrib>STJERNSCHANTZ Camilla</creatorcontrib><creatorcontrib>HIRVELA Leena</creatorcontrib><creatorcontrib>HAKOLA Marjo</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LINNANEN Tero</au><au>KOSKIMIES Pasi</au><au>STJERNSCHANTZ Camilla</au><au>HIRVELA Leena</au><au>HAKOLA Marjo</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>15beta-(3-propanamido)-substituted estra-1,3,5(10)-trien-17-oximes for use in inhibition of 17beta-hydroxysteroid dehydrogenases</title><date>2024-05-01</date><risdate>2024</risdate><abstract>The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereofwherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; heb
recordid cdi_epo_espacenet_IL294140B1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
STEROIDS
title 15beta-(3-propanamido)-substituted estra-1,3,5(10)-trien-17-oximes for use in inhibition of 17beta-hydroxysteroid dehydrogenases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T14%3A34%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LINNANEN%20Tero&rft.date=2024-05-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EIL294140B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true